This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Top Growth Picks to Avoid Tax Tangle in MedTech
by Zacks Equity Research
Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.
VWR's New Kitting Center in Czech Republic to Boost EMEA Arm
by Zacks Equity Research
VWR's new strategically located 35,000 square foot facility in Skalice, Czech Republic looks to drive the company's business growth in the high-prospect EMEA region.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
VWR Corp (VWR) Down 3.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
VWR Corp (VWR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Product Stocks Q1 Earnings Slated on May 5: VWR, SNN
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.
Is VWR Corp. (VWR) a Great Stock for Value Investors?
by Zacks Equity Research
Is VWR Corp. a great pick from the value investor's perspective right now? Read on to know more.
VWR Corporation (VWR): Q4 Lacks Shine, Currency Woes Remain
by Zacks Equity Research
On Mar 9, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR) -- a global provider of products, services and solutions to laboratory and production facilities.
VWR Corp Poised on Strong Earnings Amid Currency Headwinds
by Zacks Equity Research
On Feb 28, we issued an updated research report on VWR Corporation (VWR), an independent worldwide provider of products, services and solutions to laboratory and production facilities.
VWR Corporation (VWR) Tops Earnings in Q4; View Dull
by Zacks Equity Research
VWR Corporation (VWR) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 45 cents, reflecting a 4.3% decline from the year-ago quarter.
Medical Product's Q4 Earnings on Feb 24: VWR, SARTF, HMSY
by Zacks Equity Research
Let's take a look at the major Medical Product stocks slated to release their fourth-quarter 2016 numbers on Feb 24.
VWR Buys SEASTAR CHEMICALS to Boost Americas Division
by Zacks Equity Research
VWR Corporation (VWR) recently announced the acquisition of Canada-based SEASTAR CHEMICALS Inc.
Can VWR Corp. be a Top Choice for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
VWR Plagued by Headwinds, Solid Fundamentals Raise Hope
by Zacks Equity Research
On Dec 20, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).